Reported 1 day ago
Exagen Inc. (XGN) is a molecular diagnostics company focused on autoimmune diseases, particularly lupus and rheumatoid arthritis, with its leading product, AVISE CTD, offering superior diagnostic capabilities. With the autoimmune diagnostics market expanding, recent innovations, and a favorable financial outlook, analysts present a bullish case for Exagen, highlighting its potential for significant upside from current stock levels. The company is expected to achieve profitability by late 2025, positioning itself as an attractive option for investors amid rising interest from pharmaceutical partners.
Source: YAHOO